AKCA - Akcea Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
29.98
+1.81 (+6.43%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close28.17
Open28.00
Bid29.90 x 800
Ask31.55 x 1400
Day's Range28.00 - 30.40
52 Week Range15.23 - 40.75
Volume515,441
Avg. Volume384,543
Market Cap2.675B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.38
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est41.75
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Phase 2 Results on AKCEA-APO(a)-LRx Presented in Late-Breaking Clinical Trial Presentation at AHA Scientific Sessions

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that data from the Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), were presented in a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10, 2018. It is estimated that there are 8 to 10 million treatable patients living with cardiovascular disease and elevated levels of Lp(a).

  • GlobeNewswire9 days ago

    Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will  be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018. AKCEA-APO(a)-LRx is designed to inhibit production of apolipoprotein(a), or Apo(a) protein, thereby reducing systemic levels of lipoprotein(a), or Lp(a). It is estimated that there are 8 to 10 million treatable patients living with cardiovascular disease and elevated levels of Lp(a).

  • GlobeNewswire11 days ago

    Akcea Therapeutics to Present at Upcoming Investor Conferences

    Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

  • GlobeNewswire12 days ago

    Akcea Reports Financial Results and Highlights for Third Quarter 2018

    TEGSEDITM (inotersen) Approved in United States, European Union & Canada        $320 million to fund the company through key milestones Conference Call.

  • Benzinga12 days ago

    Akcea Therapeutics Q3 Earnings Preview

    On Monday, Nov. 5, Akcea Therapeutics (NASDAQ: AKCA ) will release its latest earnings report. Benzinga's report can help you figure out the ins and outs of the earnings release. Earnings and Revenue Analysts ...

  • GlobeNewswire15 days ago

    Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness Day on November 2, 2018. FCS Awareness Day, which will occur annually on the first Friday in November, is a global observance to build broader awareness of the challenges associated with the disease. “We are very proud to recognize the first global FCS Awareness Day along with all members of the FCS community around the world.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: Akcea Therapeutics and Tilray

    NEW YORK, NY / ACCESSWIRE / October 30, 2018 / U.S. equities continued to drop on Monday as losses in the energy and tech sectors added to the ongoing trade concerns between the U.S. and China. The Dow ...

  • GlobeNewswire22 days ago

    Investor Expectations to Drive Momentum within Adient, BT Group, The Kraft Heinz, Teladoc, Oracle, and Akcea Therapeutics — Discovering Underlying Factors of Influence

    NEW YORK, Oct. 26, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire26 days ago

    Akcea Therapeutics to Hold Third Quarter 2018 Financial Results Webcast

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Monday, November 5th at 4:30 p.m. Eastern Time to discuss its third quarter 2018 financial results and report on pipeline and business progress. Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. (IONS), is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious and rare diseases. All six drugs were discovered by and are being co-developed with Ionis, a leader in antisense therapeutics, and are based on Ionis’ proprietary antisense technology.

  • Here's Why Ionis Pharmaceuticals Rose 12.9% in September
    Motley Foollast month

    Here's Why Ionis Pharmaceuticals Rose 12.9% in September

    The stock recovered from a surprising rejection at the end of August, but has tumbled once again in the first half of October.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Arbutus Biopharma and Akcea Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 10, 2018 / U.S. equities finished mostly lower on Tuesday as interest rate increases and rising bond yields continued to put pressure on stocks. The Dow Jones Industrial ...

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Akcea Therapeutics and Tandem Diabetes Care

    NEW YORK, NY / ACCESSWIRE / October 8, 2018 / U.S. equities plunged on Friday as concerns over rising interest rates countered upbeat economic data. U.S. unemployment rate dropped to 3.7 percent, its lowest ...

  • GlobeNewswirelast month

    Akcea Announces Changes to Board of Directors

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc. today announced that Damien McDevitt, Ph.D. Chief Business Officer of Ionis Pharmaceuticals, is joining the Akcea Board of Directors to replace Ionis Founder, Chairman and CEO Stanley T. Crooke, M.D., Ph.D. who has resigned from Akcea’s Board of Directors.

  • Cambridge's Akcea rebounds with FDA approval of first drug
    American City Business Journalslast month

    Cambridge's Akcea rebounds with FDA approval of first drug

    After having one of its drugs rejected by the FDA in August, Cambridge biotech Akcea Therapeutics Inc. turned the tide on Friday, receiving approval for another treatment for a rare genetic disease. The FDA approved Tegsedi, known generically as inotersen, an RNA-based drug that is designed to treat a rare and often fatal genetic disease called hereditary ATTR amyloidosis, or hATTR amyloidosis. According to Akcea (Nasdaq: AKCA), the drug works by slowing down production of a protein that can build up and impede nervous system and organ functions.

  • Reuterslast month

    Akcea Therapeutics genetic disease treatment gets FDA approval

    Akcea Therapeutics Inc said on Friday its treatment, developed along with Ionis Pharmaceuticals , which targets a rare genetic disease was approved by the U.S. Food and Drug Administration. Akcea's once-weekly injection, Tegsedi, treats hereditary ATTR amyloidosis patients with polyneuropathy. Polyneuropathy, a symptom of the disease, is the simultaneous malfunction of peripheral nerves in the body resulting in tingling, numbness and kidney dysfunction.

  • GlobeNewswirelast month

    Akcea Announces Its Access and Distribution Strategy for TEGSEDI™ (inotersen)

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc.(IONS), announced today that they are working together with Accredo® specialty pharmacy, a subsidiary of Express Scripts (ESRX), to distribute TEGSEDI™ (inotersen) subcutaneous injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Approved by the U.S. Food and Drug Administration (FDA) today, TEGSEDI is the first and only subcutaneous RNA-targeting therapeutic offering patients an effective treatment for the polyneuropathy of hATTR amyloidosis.

  • GlobeNewswirelast month

    Akcea and Ionis Receive FDA Approval of TEGSEDI™ (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

    Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), announced today that the U.S. Food and Drug Administration (FDA) has approved TEGSEDITM (inotersen) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. TEGSEDI is now approved in the U.S., European Union and Canada. “TEGSEDI is the first and only RNA-targeting therapeutic that powerfully reduces the production of TTR protein through a once-weekly subcutaneous injection offering patients an effective treatment for people living with polyneuropathy caused by hATTR amyloidosis.

  • Benzingalast month

    The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...

  • GlobeNewswirelast month

    Akcea and Ionis Announce Approval of TEGSEDI™ (inotersen injection) in Canada

    Following a priority review by Health Canada, TEGSEDI, an RNA-targeted therapeutic, is the first treatment approved for Canadians living with hATTR amyloidosis, a disease caused by the abnormal formation of the transthyretin (TTR protein), resulting in TTR amyloid deposits in various tissues and organs throughout the body.

  • Are Options Traders Betting on a Big Move in Akcea (AKCA) Stock?
    Zacks2 months ago

    Are Options Traders Betting on a Big Move in Akcea (AKCA) Stock?

    Investors need to pay close attention to Akcea (AKCA) stock based on the movements in the options market lately.

  • ACCESSWIRE2 months ago

    Today's Research Reports on Trending Tickers: Akcea Therapeutics and Alexion Pharmaceuticals

    The Trump administration imposed a tariff of 10 percent on over $200 billion, which could increase to 25 percent if the two countries are unable to settle, according to L. Thomas Block, Washington policy strategist at Fundstrat Global Advisors. The Nasdaq Composite Index rose 0.08 percent to close at 7,993.25.

  • GlobeNewswire2 months ago

    New Research: Key Drivers of Growth for Akcea Therapeutics, Intel, Freeport-McMoRan, Sirius XM, Spark Energy, and General Motors — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Sept. 25, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx

    CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) --  Akcea Therapeutics, Inc. (AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (IONS), today announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).  Additional data from the Phase 2 study will be presented as a late-breaking clinical trial presentation at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018. The goal of the Phase 2 study was to characterize the safety and tolerability of AKCEA-APO(a)-LRx and to inform dose and dose frequency selection for the planned Phase 3 cardiovascular outcomes study.  The randomized, double-blind, placebo-controlled, dose-ranging study included 286 patients with established CVD and high Lp(a) (baseline mean of approximately 100 mg/dL [250 nmol/L] – more than three times the upper limit of normal).

  • Reuters2 months ago

    Akcea Therapeutics to cut about 10 pct of workforce

    Akcea Therapeutics Inc said on Thursday it planned to cut its workforce by about 10 percent after the U.S. health regulator declined to approve its Waylivra drug for treating a genetic disease that causes fat accumulation in blood. The company said it expected to book charges of $2 million to $2.5 million in the third quarter https://www.sec.gov/Archives/edgar/data/1662524/000114036118037945/form8k.htm, as a result of the decision, which affects only U.S. employees involved in functions focused on Waylivra.